Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China · Delayed Price · Currency is CNY 12.13
+0.18 (1.51%)
Feb 4, 2026, 3:04 PM CST
SHE:002900 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 812.96 | 1,071 | 1,153 | 1,008 | 910.39 | 1,333 |
Other Revenue | 61.64 | 61.64 | 34.09 | 20.27 | 35.41 | 5.72 |
| 874.6 | 1,132 | 1,187 | 1,028 | 945.8 | 1,339 | |
Revenue Growth (YoY) | -20.70% | -4.58% | 15.40% | 8.73% | -29.36% | -36.31% |
Cost of Revenue | 481.09 | 553.88 | 475.55 | 360.34 | 312.86 | 487.25 |
Gross Profit | 393.51 | 578.6 | 711.23 | 668.08 | 632.94 | 851.63 |
Selling, General & Admin | 448.44 | 432.05 | 598.15 | 594.6 | 667.1 | 734.35 |
Research & Development | 93.11 | 105.22 | 112.81 | 89.27 | 99.92 | 112.02 |
Other Operating Expenses | 9.04 | 7.39 | 11.1 | 15.53 | 14.14 | 15.77 |
Operating Expenses | 550.25 | 545.88 | 719.2 | 699.98 | 782.97 | 865.92 |
Operating Income | -156.74 | 32.72 | -7.97 | -31.91 | -150.03 | -14.29 |
Interest Expense | -27.8 | -30.98 | -22.89 | -22.62 | -13.8 | -9.33 |
Interest & Investment Income | 34.08 | 55.45 | 70.54 | 74.24 | 609.35 | 18.54 |
Currency Exchange Gain (Loss) | 0.51 | 0.51 | 0.14 | 1.57 | -0.02 | -0.34 |
Other Non Operating Income (Expenses) | 0.78 | 3.63 | -0.26 | -1.06 | -0.37 | -0.46 |
EBT Excluding Unusual Items | -149.18 | 61.34 | 39.56 | 20.22 | 445.12 | -5.87 |
Gain (Loss) on Sale of Investments | -16.96 | -14.64 | 13.37 | 13.87 | -5.13 | -37.36 |
Gain (Loss) on Sale of Assets | -0.13 | 0.19 | -2.61 | -13.31 | -1.92 | -4.37 |
Asset Writedown | -52.75 | -0 | -0 | -2.91 | -0.68 | -0.04 |
Other Unusual Items | 13.44 | 13.11 | 31.06 | 22.2 | 15.45 | 80.79 |
Pretax Income | -205.59 | 60.01 | 81.37 | 40.07 | 452.86 | 33.16 |
Income Tax Expense | -11.59 | 5.03 | 11.3 | 13.57 | 103.18 | 6.52 |
Earnings From Continuing Operations | -194 | 54.98 | 70.08 | 26.5 | 349.68 | 26.63 |
Minority Interest in Earnings | 3.25 | 3.7 | 3.58 | 3.71 | 1.27 | 2.69 |
Net Income | -190.75 | 58.68 | 73.66 | 30.21 | 350.95 | 29.32 |
Net Income to Common | -190.75 | 58.68 | 73.66 | 30.21 | 350.95 | 29.32 |
Net Income Growth | - | -20.35% | 143.86% | -91.39% | 1096.77% | -83.45% |
Shares Outstanding (Basic) | 312 | 309 | 307 | 302 | 311 | 326 |
Shares Outstanding (Diluted) | 312 | 309 | 307 | 302 | 311 | 326 |
Shares Change (YoY) | 2.72% | 0.61% | 1.61% | -2.74% | -4.68% | 4.82% |
EPS (Basic) | -0.61 | 0.19 | 0.24 | 0.10 | 1.13 | 0.09 |
EPS (Diluted) | -0.61 | 0.19 | 0.24 | 0.10 | 1.13 | 0.09 |
EPS Growth | - | -20.83% | 140.00% | -91.15% | 1155.56% | -84.21% |
Free Cash Flow | -131.69 | -315.52 | -263.89 | 55.42 | -86.48 | -150.36 |
Free Cash Flow Per Share | -0.42 | -1.02 | -0.86 | 0.18 | -0.28 | -0.46 |
Dividend Per Share | 0.200 | 0.200 | 0.200 | 0.100 | 0.320 | 0.080 |
Dividend Growth | - | - | 100.00% | -68.75% | 300.00% | -71.43% |
Gross Margin | 44.99% | 51.09% | 59.93% | 64.96% | 66.92% | 63.61% |
Operating Margin | -17.92% | 2.89% | -0.67% | -3.10% | -15.86% | -1.07% |
Profit Margin | -21.81% | 5.18% | 6.21% | 2.94% | 37.11% | 2.19% |
Free Cash Flow Margin | -15.06% | -27.86% | -22.23% | 5.39% | -9.14% | -11.23% |
EBITDA | -54.64 | 133.24 | 90.43 | 65.02 | -60.22 | 65.66 |
EBITDA Margin | -6.25% | 11.77% | 7.62% | 6.32% | -6.37% | 4.90% |
D&A For EBITDA | 102.11 | 100.52 | 98.41 | 96.92 | 89.81 | 79.95 |
EBIT | -156.74 | 32.72 | -7.97 | -31.91 | -150.03 | -14.29 |
EBIT Margin | -17.92% | 2.89% | -0.67% | -3.10% | -15.86% | -1.07% |
Effective Tax Rate | - | 8.38% | 13.88% | 33.87% | 22.78% | 19.68% |
Revenue as Reported | 874.6 | 1,132 | 1,187 | 1,028 | 945.8 | 1,339 |
Advertising Expenses | - | 16.62 | 51.46 | 43.24 | 31.69 | 48.89 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.